Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2001

View Archived Issues

Current enrollment accelerating in Emisphere's phase III oral heparin program

Tanox opens enrollment for phase I trial of TNX-355 for HIV

GC-C agonists inhibit colon cancer cell proliferation

Texas Biotechnology announces approval of argatroban in Canada

Early c-Fos induction appears to have neuroprotective role in cerebral ischemia

Phase I trial of oral gluconeogenesis inhibitors for diabetes mellitus set to begin

Long-terms effects of Ac-SDKP assessed in rat model of renovascular hypertension

FDA approves DuPont Pharmaceutical's ultrasound contrast agent Definity

Abbott Laboratories submits NDA for Synthroid ahead of schedule

Novel leukemia drug receives positive opinion from CPMP

Polydex reports latest advancements for development of Usherdex for lung disorders

Letrozole may increase adult height in boys with delayed puberty

ViroPharma files NDA for pleconaril for the treatment of viral respiratory infection in adults

Phase II trial of ABX-EGF for non-small cell lung cancer initiated

Corixa receives milestone payment for lung cancer vaccine

Patient enrollment completed in Xcytrin phase II clinical trial for glioblastoma multiforme

Memantine to be evaluated in the treatment of diabetic neuropathy

Use of beta-adrenoceptor antagonists for treating outer retina disorders described

Ono Pharmaceutical presents a new series of cysteine protease inhibitors

VLA-4 integrin antagonists presented by Novartis

Novel adamantane derivatives and their use described by AstraZeneca

Compounds useful for the treatment of chronic inflammatory diseases patented by F. Hoffmann-La Roche

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...